SCHEMBL2310679

SCHEMBL2310679

COc1cc(C(N)=O)c(N)cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.51
HTT P42858 4/20 0.49
LMNA P02545 3/20 0.49
ALDH1A1 P00352 3/20 0.44
GAA P10253 2/20 0.44
GLA P06280 1/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.42
RAB9A P51151 1/20 0.42
PARP10 Q53GL7 2/20 0.42
PARP15 Q460N3 1/20 0.42
PARP14 Q460N5 1/20 0.42
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
AR P10275 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAP2K1 Q02750 1/20 0.38
CYP3A4 P08684 1/20 0.38
JAK2 O60674 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3801667 0.86 KDM4E (0.47) KDM4EHTTLMNAALDH1A1GAA
SCHEMBL7019323 0.86 KDM4E (0.51) KDM4EHTTLMNAALDH1A1GAA
SCHEMBL4165532 0.86 KDM4E (0.51) KDM4EHTTLMNAALDH1A1GAA
SCHEMBL30408027 0.86 KDM4E (0.51) KDM4EHTTLMNAALDH1A1GAA
SCHEMBL348568 0.85 KDM4E (0.69) KDM4EHTTLMNAALDH1A1GAA
SCHEMBL3424917 0.84 KDM4E (0.74) KDM4EHTTLMNAALDH1A1GAA
SCHEMBL13254935 0.82 NNMT (0.47) KDM4EHTTLMNAALDH1A1GAA
SCHEMBL25266060 0.81 KDM4E (0.47) KDM4EHTTLMNAALDH1A1MAPK1
SCHEMBL31281299 0.81 HMGCR (0.54) KDM4EHTTLMNAMAPK1RAB9A
SCHEMBL5860108 0.81 HMGCR (0.54) KDM4EHTTLMNAMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888579-B1 NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF AVENTIS PHARMA SA (FR) 2011-08-03 EP disclosed
US-7674795-B2 Fluorene derivatives, composition containing said derivatives and the use thereof AVENTIS PHARMA SA (FR) 2010-03-09 US disclosed
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-26 US disclosed
EP-1888579-A2 NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF Aventis Pharma S.A. (FR) 2008-02-20 EP disclosed
WO-2006123061-A2 FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF AVENTIS PHARMA S.A. (FR) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof HSP90B1, HSP90AB1, HSP90AA1 KDM4E 3419/4885HTT 338/4885LMNA 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.